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Sudden cardiac death (SCD) is mostly caused by ventricular
ﬁbrillation (VF) during acute myocardial infarction (MI). MI results
from thrombotic coronary occlusion. Previously, we reported that
activated blood platelet products (ABPP) facilitate VF occurrence by
increasing intracellular Ca2+ (Ca2+i) transients and L-type Ca2+ current
(ICa,L) in cardiac myocytes [1]. Trypsin reduced these effects, suggesting
involvement of peptides. Activated platelets release numerous sub-
stances including arachidonic-acid products and platelet-derived
microvesicles (MV). Arachidonic-acid is released from phospholipids
of theplatelet plasmamembrane. Cyclooxygenase converts arachidonic-
acid into prostaglandins and thromboxane. These substances are
involved in various processes, including platelet aggregation, vasocon-
striction, and inﬂammation. Acetylsalicylic acid (ASA) blocks
thromboxane-dependent platelet activation by inhibiting cyclooxygen-
ase. The beneﬁcial cardiovascular effects of ASA aremainlyascribed to its
antithrombotic actions. Whether ASA has antiarrhythmic properties in
humans is unknown. Globular membrane fragments called MV include
plasmamembrane-derivedmicroparticles and body-derived exosomes,
and are a major source of ligands released by activated platelets,
containing hundreds of proteins, bioactive lipids, growth factors, and
other compounds [2,3]. MV play an important pleiotropic role in many
biological processes, e.g., hemostasis, maintenance of vascular health,
and immunity [3]. However, theirdirect effect onventricularmyocytes is
unknown. In our search for the arrhythmia-inducing agent(s) in ABPP,
we focused here on cyclooxygenase products and MV.
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Table 1
The characteristics of the included studies.
APPLE, 2012 [5] (N=221) LAPS, 2011 [6] (N=200) Mok et al., 2011 [7] (N=72)
Participants Children and adolescents with
SLE
Adult with SLE Adult with SLE
Intervention Medication Atorvastatin
10–20 mg Qd
Placebo Atorvastatin
40 mg Qd
Placebo Rosuvastatin
10 mg Qd
Placebo
Duration (months) 36 36 24 24 24 24
Sample size (n) 113 108 99 101 36 36
Traditional cardiovascular risk factors Age (years) 15.7±2.8a 15.8±2.5 44.7±11.3 51.3±10.4 50.3±9.2
Female (%) 84.1 82.4 90 94 94 100
Body mass index (kg/m2) 25.0±5.2 23.8±5.4 NA NA NA
Smoking (%) 2.7 3.7 NA NA NA
Hypertension (%) 34.2 34 49 48 39 28
Diabetes (%) NA NA 4 5 6 0
Cholesterol (mg/dl) 159.6±41.1 150.6±34.0 186±38 185.6±42.5 180.2±37.5
LDL-C (mg/dl) 91.8±33.0 80.7±28.7 103±31 101.3±40.2 93.6±34.8
HDL-C (mg/dl) 46.7±12.9 46.0±12.7 NA 57.2±13.5 63.0±16.2
Triglyceride (mg/dl) 105.5±52.8 122.9±77.3 NA 141.0±66.4 116.4±61.8
SLE related factors SLEDAI 4.92±4.46 4.57±4.07 2.2 (0–24)b 2.0 (0–18) 1.4±1.5 1.8±2.0
Duration of SLE (months) 32.5±29.1 29.4±27.8 N10 years (48%)c N10 years (34%) 12.4±8.1 11.2±5.9
Concomitant use of medications Aspirin (%) 62.8 70.4 NA 50 50
HCQ (%) 97.3 95.4 NA 39 53
Corticosteroids (%) 81.3 82.4 NA 69 64
Baseline CIMT measurement (mm) Max CIMT 0.579±0.059 0.587±0.053 NA NA
Mean CIMT 0.465±0.0439 0.471±0.0409 0.59 0.57 0.68±0.11 0.66±0.15
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity
index; HCQ: hydroxychloroquine; CIMT: carotid intima-media thickness; NA: not available.
a Mean±standard deviation.
b Median (range).
c Percentage of patients with durationN10 years.
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The study was approved by the institutional Medical Ethics
Committee and the institutional animal experiments committee, and
conforms to the principles outlined in the Declaration of Helsinki and
the Guide for the Care and Use of Laboratory Animals (NIH Publication
85–23, revised 1996). Informed consentwasobtained fromeach subject.
Blood platelets were isolated from fresh citrated platelet-rich-plasma of
healthy volunteers (n=3) and suspended to a concentration of 220–
250×109/L in Tyrode's solution [1]. One portion of this suspension was
ﬁltratedwith 0.45 μmpore-size syringe ﬁlters and snap-frozen in liquid
nitrogen; the resulting solution contained non-activated blood platelet
products (NABPP). The remaining portion of the suspension was
activated by thrombin receptor activating protein and ﬁltrated
to obtain ABPP solution. Platelet activation was controlled by CD62p
(α-granule membrane glycoprotein) and CD63 (lysosomal integral
Fig. 1. ASA abolished the effects of ABPP. (A) Typical Ca2+i transients in control condition and in the presence of ABPP+ASA. (B) Average Ca2+i transient parameters. ⁎Pb0.05 ABPP
(n=10) versus NABPP (n=9), ABPP+ASA (n=17) and ABPPpatient+ASA (n=10). (C) Representative ICa,L activated upon depolarizing voltage steps to 0 mV in control conditions
and in the presence of ABPP+ASA. Inset: protocol used. (D) Average ICa,L measured at 0 mV. ⁎Pb0.05 ABPP (n=6) versus NABPP (n=4) and ABPP+ASA (n=14). Data are
normalized to their control conditions, i.e., in the absence of NABPP, ABPP, ABPP+ASA or ABPPpatient+ASA.
Fig. 2. MV had no inﬂuence on Ca2+i transients. (A, B, C) Typical Ca2+i transients in control conditions and in the presence of ABPP, ABPP-without-MV, and MV, respectively.
(D) Average effects of NABPP (n=9), ABPP (n=10), ABPP-without-MV (n=6), and MV (n=5) on Ca2+i parameters. ⁎Pb0.05 ABPP versus NABPP and MV. Data are normalized to
their control conditions, i.e., in the absence of NABPP, ABPP, ABPP-without-MV, or MV.
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membrane protein) labeling. We inhibited cyclooxygenase by incubat-
ing platelet-rich-plasma with 0.02 mg/ml ASA for 15 min; this yielded
ABPP+ASA or NABPP+ASA. Incubation with ASA had no effect on
Ca2+i (data not shown). We also studied ASA effects in patients who
experiencedVFduringMI (n=2). In thesepatients, cyclooxygenasewas
inhibited bychronicASA treatment following theirMI. Accordingly, their
platelet-rich-plasma was not incubated with ASA (ABPPpatient+ASA).
MV were isolated by centrifugating ABPP aliquots (1 ml) for 1 h at
154000 g and 4 °C [4]. ABPP without MV (ABPP-without-MV),
present in the upper 0.5 ml, was harvested by aspiration. The
remaining pellet, containing MV, was resuspended in 1 ml Tyrode's
solution. Midmyocardial left ventricular myocytes of New Zealand
white rabbits were enzymatically isolated [5]. Ca2+i was measured at
37 °C in indo-1 loaded myocytes stimulated at 2 Hz using ﬁeld
stimulation [6]. Myocytes were superfused with Tyrode's solution
containing (mM): NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1.0, glucose 5.5,
HEPES 5.0; pH 7.4 (NaOH). We analyzed diastolic and systolic Ca2+i
concentrations, and Ca2+i transient amplitudes (Tr amplitude). ICa,L was
measured at 37 °C using the ruptured whole-cell conﬁguration of the
patch-clamp technique [1]. Extracellular solution for ICa,Lmeasurements
contained (mM): TEA-Cl 145, CsCl 5.4, CaCl2 1.8, MgCl2 1.0, glucose 5.5,
HEPES 5.0; pH 7.4 (NMDG-OH). Pipette solution for ICa,L measurements
contained (mM): CsCl 145, K2-ATP 5.0, EGTA 10, HEPES 10; pH 7.2
(NMDG-OH). ICa,L was measured in the presence of 0.25 mM 4,4′
diisothiocyanatostilbene-2,2′-disulfonic acid (to block Ca2+-activated
Cl− current [7]) with a double-pulse protocol (Fig. 1C). During the
ﬁrst depolarizing pulse (P1), ICa,L activates. This current was used to
analyze ICa,L amplitude and voltage-dependence of activation; the
second pulse (P2) was used to measure voltage-dependence of
inactivation. Voltage-dependence of (in)activation was determined by
ﬁtting a Boltzmann function (y=[1+exp{(V−V1/2)/k}])−1 to the
individual curves, yielding half-maximal voltage V1/2 and slope factor k.
Ca2+i and ICa,L weremeasured in paired experiments, i.e., in the absence
or presence of NABPP or ABPP (40× dilution) in the samemyocyte. Data
werenormalized to the control condition, i.e., in the absence ofNABPPor
ABPP, and presented as mean±SEM. Group comparisons were made
using one-way repeated measures ANOVA followed by pairwise
comparison using the Student–Newman–Keuls test. Pb0.05 deﬁned
statistical signiﬁcance.
In accordance with our previous study [1], we found that ABPP
increased systolic Ca2+i, Tr amplitude, and ICa,L amplitude signiﬁcantly by
28%, 39%, and 14%, respectively,whileNABPPdid not affect these variables
(Fig.1). ASA strongly attenuated these effects (10%,15%, and 3% increases,
respectively). The effects of ASA were similar in VF patients (ABPP-
patient+ASA). Voltage-dependence of (in)activation of ICa,L was not
signiﬁcantly affected by NABPP, ABPP or ABPP+ASA. The effects of
ABPP-without-MV on systolic Ca2+i and Tr amplitude (22% and 29%
increases, respectively)were similar to those of ABPP,whileMValonehad
no effects (Fig. 2). Because these ﬁndings suggest that MV had no effects
on Ca2+i homeostasis, we did not test possible effects of MV on ICa,L, as
Ca2+i homeostasis and ICa,L are closely linked.
In summary, ASA pretreatment signiﬁcantly reduced the effects of
ABPP on Ca2+i and ICa,L, pointing to an important role of the
cyclooxygenase pathway. In contrast, ABPP from which MV were
removed had similar effects on Ca2+i as ABPP that contained MV,
while MV alone had no effect on Ca2+i , indicating that MV are not
involved. This narrows down the search for the agent(s) responsible for
the proarrhythmic effects of ABPP, and eliminates hundreds of proteins
present in MV [2,3]. Cyclooxygenase products include thromboxane and
prostaglandins. Thromboxane A2 is chemically unstable (it is hydrolyzed
within ~30 s to biologically inactive thromboxane B2); thus, prostaglan-
dins are more likely candidates responsible for the observed effects of
ABPP. Our ﬁndings provide a mechanistic link between previous studies
which showed that some cyclooxygenase products of arachidonic acid
(PGF2α and stable synthetic analog of thromboxane A2) induce
tachyarrhythmias in cultured neonatal rat myocytes [8], while ASA
treatment afforded antiarrhythmic effects during balloon coronary
occlusion in dogs [9]. These effects may be based on the molecular
mechanism shown in the present study which is mediated by Ca2+i and
ICa,L. Future studies must resolve whether ABPP of VF patients exert
stronger effects on Ca2+i and ICa,L than ABPP of patients who did not
suffer VF during MI. To detect intrinsic differences between both patient
categories, these studies must be conducted in the absence of ASA,
because we demonstrated that ASA strongly attenuated the effects of
ABPP on Ca2+i and ICa,L (and that the effects of ASA-treated ABPP were
similar in healthy volunteers and VF patients). Thus, ASA treatment may
mask possible differences between both patient categories.
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